Week In Review: AffaMed Announced US Approval To Start Clinical Trials
February 19, 2022 at 14:15 PM EST
AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma. On Saturday, AffaMed announced US approval to start clinical trials of the candidate, AM712.
